| CTT Meta-Analysis: No Cancer Risk With Statins |
| 02/09/2010 |
|
|
Investigators of Cholesterol Trialists' Collaboration provided evidence that statins do not increase the risk of developing cancer. They reported that statin therapy had no adverse effect on any cancer type, irrespective of how long patients took the cholesterol-lowering medications.
The results of the large meta-analysis were formally presented at the European Society of 2010 Cardiology Congress (August 30, 2010 (Stockholm, Sweden)
Meta-analysis included the data of 21 studies, counting more than 130000 patients, compared statins vs placebo controls; five studies, with approximately 40000 patients, examined different statin doses. The number of patients who developed cancer was nearly identical in the statin and control arms and in the statin trials comparing higher vs lower doses.
In all studies, there was no increased risk of cancer with statin therapy, and there was no increased risk observed among patients treated with higher statin doses.
In addition, there was no increased incidence of cancer when investigators analyzed the rates of disease among patients by baseline LDL-cholesterol levels, including levels <77 mg/dL, or by duration of treatment. Similarly, there was no increased risk of any specific types of cancer, such as breast, prostate, bladder, or hematological cancers.
|
Source information
European Society of 2010 Cardiology Congress, August , 2010 (Stockholm, Sweden)
|
|
